Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 100 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Alexia L.

France

USD 100 /hr

Freelance Statistician with 20 years of experience | Clinical research | Epidemiology | PhD | R and SAS |

Profile Summary

Hi! I have been working as a biostatistician in a public hospital, close to the MDs from various areas and also in a pharmaceutical company and I created my own business in March 2020 (Please have a look at my website QualityStat.fr) I am able to understand rapidly the objectives of the research and the requests. I am author or co-author of 40+ manuscripts in biostatistics and medical research. I can propose appropriate designs, write statistical analysis plans, program in R or SAS, review statistical analyses and contribute to manuscript or poster development by drawing nice and meaningful figures. I am looking forward to helping you for your project!

Subject Matter Expertise

• ★ Biostatistics
• ★ Medical Statistics

Services

• Writing
• Data & AI

Writing Technical Writing

Data & AI Statistical Analysis

Work Experience

QualityStat - self-employed biostatistician

March 2020 - Present

Project Leader Statistician

Sanofi

April 2014 - February 2020

Biostatistician

Cegedim Strategic Data

September 2011 - March 2014

Biostatistician

Bicêtre Hospital

April 2006 - August 2011

Post-doctoral contract in Biostatistics

INSERM

January 2004 - February 2006

Teacher in epidemiology and mathematics - during my PhD

Paris V University

September 2000 - August 2004

Education

PhD (Biostatistics)

University of Paris-Sud

- December 2003

MSc in Mathematics

Lille University

September 1997 - August 1998

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, et al.(2019). Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies . Cardiovascular diabetology.

Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, et al.(2019). Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery . Journal of the American College of Cardiology.

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP(2019). Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control . Atherosclerosis.

Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos RD, Ferdinand KC, Wright RS, Navarese EP, et al.(2019). Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies . Journal of clinical lipidology.

Bruckert E, Kereiakes DJ, Koren MJ, Louie MJ, Letierce A, Miller K, Cannon CP(2019). PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab . Journal of clinical lipidology.

Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH(2018). Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials . Diabetic medicine : a journal of the British Diabetic Association.

Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KK(2018). Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials . Journal of the American Heart Association.

Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM(2018). Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial . Atherosclerosis.

Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, Letierce A, Leiter LA(2018). Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials . Diabetes, obesity & metabolism.

Ginsberg HN, Farnier M, Robinson JG, Cannon CP, Sattar N, Baccara-Dinet MT, Letierce A, Bujas-Bobanovic M, Louie MJ, Colhoun HM(2018). Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies . Diabetes therapy : research, treatment and education of diabetes and related disorders.

Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, et al.(2018). Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial . Diabetes, obesity & metabolism.

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN(2018). Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials . Diabetes, obesity & metabolism.

Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, et al.(2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease . Kidney international.

Martelli C, Petillion A, Brunet-Lecomte M, Miranda Marcos R, Chanraud S, Amirouche A, Letierce A, Kostogianni N, Lemaitre H, Aubin HJ, et al.(2017). Neuropsychological Impairment in Detoxified Alcohol-Dependent Subjects with Preserved Psychosocial Functioning . Frontiers in psychiatry.

Leiter LA, Müller-Wieland D, Baccara-Dinet MT, Letierce A, Samuel R, Cariou B(2017). Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials . Diabetic medicine : a journal of the British Diabetic Association.

Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, et al.(2017). Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk . Cardiovascular diabetology.

Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, et al.(2017). Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial . Diabetes & metabolism.

Cros J, Sbidian E, Posseme K, Letierce A, Guettier C, Benoît G, Ferlicot S(2016). Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma . Virchows Archiv : an international journal of pathology.

Letierce A, Jouaville SL, Boutmy E(2014). Understanding Real Life Treatment Patterns Among Patients With Hypertension: A Markov Model . Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cotté FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, Huguet M(2014). Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries . Clinical therapeutics.

Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, et al.(2013). Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial . Annals of internal medicine.

Durand P, Debray D, Kolaci M, Bouligand J, Furlan V, Fabre M, Letierce A, Verstuyft C, Becquemont L(2013). Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism . Pharmacogenomics.

Fournier-Charrière E, Tourniaire B, Carbajal R, Cimerman P, Lassauge F, Ricard C, Reiter F, Turquin P, Lombart B, Letierce A, et al.(2012). EVENDOL, a new behavioral pain scale for children ages 0 to 7 years in the emergency department: design and validation . Pain.

Kamenický P, Blanchard A, Gauci C, Salenave S, Letierce A, Lombès M, Brailly-Tabard S, Azizi M, Prié D, Souberbielle JC, et al.(2012). Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? . The Journal of clinical endocrinology and metabolism.

Koné-Paut I, Bello MD, Shahram F, Gattorno M, Cimaz R, Chkirate B, Bouayed K, Hofer M, Ozen S, Anton J, et al.(2011). International cohort study for pediatric Behçet’s Disease: update 2011 . Pediatric rheumatology online journal.

Tran T, Monteil S, Letierce A, Terrier B, Geri G, Saadoun D, Kone-Paut I, Salomon B, Rosenzwajg M(2011). Role of CD4CD25CD127FoxP3 regulatory T lymphocytes in the pathogenesis of Behçet’s disease in children . Pediatric rheumatology online journal.

Monnet X, Letierce A, Hamzaoui O, Chemla D, Anguel N, Osman D, Richard C, Teboul JL(2011). Arterial pressure allows monitoring the changes in cardiac output induced by volume expansion but not by norepinephrine . Critical care medicine.

Kamenicky P, Blanchard A, Frank M, Salenave S, Letierce A, Azizi M, Lombès M, Chanson P(2011). Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity . The Journal of clinical endocrinology and metabolism.

Michelon H, König J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, et al.(2010). SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients . Pharmacogenomics.

Koné-Paut I, Darce-Bello M, Shahram F, Gattorno M, Cimaz R, Ozen S, Cantarini L, Tugal-Tutktun I, Assaad-Khalil S, Hofer M, et al.(2010). Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data . Rheumatology (Oxford, England).

Kondi A, Hentgen V, Piram M, Letierce A, Guillaume-Czitrom S, Koné-Paut I(2010). Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders . Rheumatology (Oxford, England).

Carbonell N, Verstuyft C, Massard J, Letierce A, Cellier C, Deforges L, Saliba F, Delchier JC, Becquemont L(2010). CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin . Clinical pharmacology and therapeutics.

Dommergues JP, Letierce A, Gravereau L, Plainguet F, Bernard O, Debray D(2010). Current lifestyle of young adults after liver transplantation during childhood . American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Ferlicot S, Vernochet A, Romana S, Ortin-Serrano M, Letierce A, Brégerie O, Durrbach A, Guettier C(2010). Microchimerism in renal allografts: clinicopathological associations according to the type of chimeric cells . Histopathology.

Perrin L, Letierce A, Guitton C, Tran TA, Lambert V, Koné-Paut I(2009). Comparative study of complete versus incomplete Kawasaki disease in 59 pediatric patients . Joint, bone, spine : revue du rhumatisme.

Corruble E, Chouinard VA, Letierce A, Gorwood PA, Chouinard G(2009). Is DSM-IV bereavement exclusion for major depressive episode relevant to severity and pattern of symptoms? A case-control, cross-sectional study . The Journal of clinical psychiatry.

Auroux M, Volteau M, Ducot B, Wack T, Letierce A, Meyer L, Mayaux MJ(2009). Progeny's mental aptitudes in man: relationship with parental age at conception and with some environmental factors . Comptes rendus biologies.

Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L(2008). Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients . Basic & clinical pharmacology & toxicology.

Dommergues JP, Letierce A, Bernard O, Debray D(2008). [Medical follow-up, personal experiences and everyday life of young adults after liver transplantation during childhood] . Bulletin de l'Academie nationale de medecine.

Quteineh L, Verstuyft C, Durrbach A, Letierce A, Ferlicot S, Charpentier B, Becquemont L(2008). Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation . Transplantation.

Dommergues JP, Letierce A, Descots C, Debray D(2008). [Medical follow-up, everyday life and actual experience of young adults after liver transplantation in childhood] . Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C(2007). Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics . Clinical pharmacology and therapeutics.

Tubert-Bitter P, Letierce A, Bloch DA, Kramar A(2005). A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approach . Journal of biopharmaceutical statistics.

Dellatolas G, De Agostini M, Curt F, Kremin H, Letierce A, Maccario J, Lellouch J(2003). Manual skill, hand skill asymmetry, and cognitive performances in young children . Laterality.

Letierce A, Tubert-Bitter P, Kramar A, Maccario J(2003). Two-treatment comparison based on joint toxicity and efficacy ordered alternatives in cancer trials . Statistics in medicine.